此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

2015年4月21日 更新者:Pfizer

A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia

The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers. RN316 is an investigational drug that is currently being studied as a cholesterol lowering therapy.

研究概览

研究类型

介入性

阶段

  • 阶段1

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • LDL-C must be greater or equal to 130 mg/dl
  • BMI must be between 18.5 and 40 kg/m2

Exclusion Criteria:

  • History of cardiovascular or cerebrovascular event during the past year.
  • Poorly controlled type 1 or type 2 diabetes mellitus
  • Subjects who have taken lipid lowering therapies within the last 3 months of screening.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 1 mg/kg every 2 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 2 mg/kg every 4 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 4 mg/kg every 4 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 4 mg/kg every 8 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 8 mg/kg every 8 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
实验性的:RN316: 12 mg/kg every 8 weeks
Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of dose limiting or intolerable treatment related adverse events (AEs).
大体时间:Every Scheduled Visit
Every Scheduled Visit
Incidence, severity and causal relationship of treatment emergent AEs (TEAEs).
大体时间:Every Scheduled Visit
Every Scheduled Visit
Incidence of abnormal and clinically relevant safety laboratories.
大体时间:Screening and Days 29, 57, 85, 113, 135, 141, 169 and 197
Screening and Days 29, 57, 85, 113, 135, 141, 169 and 197
Abnormal and clinically relevant changes in vital signs, BP, and ECG parameters.
大体时间:Every Scheduled Visit
Every Scheduled Visit
Incidence of anti-drug-antibodies.
大体时间:Baseline and Day 15 and monthly thereafter
Baseline and Day 15 and monthly thereafter

次要结果测量

结果测量
大体时间
PK parameter estimates including but not be limited to: AUC, Tmax, Cmax terminal elimination half life (t1/2), Clearance (CL), volume of distribution at steady state (Vss), and accumulation ratio (R) of RN316.
大体时间:Day 1 and every scheduled visit thereafter
Day 1 and every scheduled visit thereafter
Absolute and percentage change in LDL C from baseline.
大体时间:Every scheduled visit except Day 1
Every scheduled visit except Day 1
Proportion of subjects who achieve a target LDL C of <100 mg/mL.
大体时间:Every scheduled visit except Day 1
Every scheduled visit except Day 1
Proportion of subjects who achieve a target LDL C of <70 mg/dL.
大体时间:Every scheduled visit except Day 1
Every scheduled visit except Day 1
Proportion of subjects achieving 50% decrease in LDL C from baseline.
大体时间:Every scheduled visit except Day 1
Every scheduled visit except Day 1

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年8月1日

初级完成 (预期的)

2011年3月1日

研究完成 (预期的)

2011年3月1日

研究注册日期

首次提交

2010年7月14日

首先提交符合 QC 标准的

2010年7月15日

首次发布 (估计)

2010年7月16日

研究记录更新

最后更新发布 (估计)

2015年4月23日

上次提交的符合 QC 标准的更新

2015年4月21日

最后验证

2015年4月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅